Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
10 févr. 2020 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that...
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
09 janv. 2020 16h27 HE
|
Aclaris Therapeutics, Inc.
• Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6• Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory Diseases WAYNE, Pa.,...
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
08 janv. 2020 08h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the...
Aclaris Therapeutics to Present at Upcoming Investor Conferences
12 nov. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that...
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
07 nov. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
Completed Strategic Review and Announced Refocusing of Resources on Immuno-inflammatory Development PipelineDivested RHOFADE® (oxymetazoline hydrochloride) cream, 1%Repaid $30 Million Term...
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
31 oct. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will...
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
24 oct. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts Highly statistically significant results for the primary efficacy endpointHighly...
Aclaris Therapeutics Announces Divestiture of RHOFADE®
10 oct. 2019 16h02 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has...
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
08 oct. 2019 17h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the...
Aclaris Therapeutics to Hold R&D Day
17 sept. 2019 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will...